Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 1, 2026

7 Social Security Changes That Take Effect Today

View original at nasdaq.com
7 Social Security Changes That Take Effect Today Key Points Nearly a quarter-century of annual surveys show that up to 90% of retirees rely on their monthly Social Security income to cover some portion of their expenses…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 80% to 90% of retired respondents rely on their Social Security income in some capacity to meet their expenses

    80% confidence

  • Around 2% of retirees achieve the maximum monthly benefit at full retirement age

    80% confidence

  • Approximately 6% of workers are expected to reach the earnings tax cap in 2026

    80% confidence

  • A 9.7% year-over-year increase in Medicare's Part B premium for 2026, coupled with robust inflation for shelter and medical care services, makes it likely that the purchasing power of a Social Security dollar will decline this year

    80% confidence

  • The 2.8% COLA will boost the average monthly retired-worker benefit by $56 to $2,071, and lift the average monthly payout for workers with disabilities by $44 to $1,630

    80% confidence

Data points we hold from this source

Social Security Administration · maximum benefit full retirement age4152 USD
Social Security Administration · beneficiary count70 millions
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
7 Social Security Changes That Take Effect Today — Source | Via News | ViaNews EU